The FDA's IND acceptance de-risks SP16's early development and validates its preclinical package. With full trial funding secured externally, Dogwood preserves its balance sheet while expanding its pipeline. Traders should monitor initiation of patient enrollment in mid-2026 as the next catalyst.
Price Chart
Executive Summary
Dogwood Therapeutics announced FDA acceptance of the IND application for its SP16 candidate, an IV treatment for chemotherapy-induced pain and neuropathy, with patient enrollment expected mid-2026. The Phase 1b trial is fully funded by a $2.5 million grant from the National Cancer Institute and sponsored by partner Serpin Pharma.
Key Financial Metrics
Key Facts
- FDA accepted the IND application for SP16 IV to treat chemotherapy-induced peripheral neuropathy (CIPPN).
- Phase 1b trial will be sponsored by Serpin Pharma and fully funded by a $2.5M grant from the National Cancer Institute.
- Patient enrollment is expected to begin mid-2026 at the University of Virginia.
- Dogwood holds a royalty-free, global license to develop and commercialize SP16 IV, secured in September 2025.
- SP16 is a first-in-class LRP1 agonist with dual hypothesized mechanisms: anti-inflammatory effects and tissue repair via pAKT/pERK pathways.
Financial Impact
$2.5 million in external funding from the National Cancer Institute covering full trial costs
Risk Factors
- Clinical development risk: SP16 is still in early-stage development with no guarantee of efficacy or safety in humans.
- Dependency on partner: Serpin Pharma is the regulatory sponsor, limiting Dogwood's control over trial execution.
- Low market cap ($60M) increases volatility and susceptibility to dilution if future financing is needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274472 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | SC 13D/A | $1.12 | awaiting T+60 | — | $1.12 (+0.16%) |
Oct 19, 2026 7d ago | 8-K | $1.21 | awaiting T+60 | — | $1.12 (−7.29%) |
Oct 19, 2026 7d ago | Press Release | $1.21 | awaiting T+60 | — | $1.12 (−7.29%) |
Aug 13, 2026 10w ago | 8-K | $1.98 | awaiting T+60 | — | $1.12 (+43.34%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.12 (−34.01%) |
May 14, 2026 23w ago | 8-K | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.34%) |
May 14, 2026 23w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.34%) |
Apr 15, 2026 27w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.12 (−34.40%) |
Mar 18, 2026 31w ago | Press Release | $2.97 $1.57 | ▼ −47.14% | ▼ −58.66% | $1.12 (−62.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers